Integra LifeSciences Holdings Corporation (IART) Posts Q3, Guides Q4 Lower; Completes $2.1B Refi
Integra LifeSciences (IART) reported Q3 revenue of $411.2M, up 2.3% YoY, and adjusted EPS of $0.59. The company guided Q4 revenue to $413M–$433M and adjusted EPS to $0.61–$0.71, reflecting a decline of up to 5.2% YoY. It also completed a $2.1B debt refinancing.
How this was made
The 30-second read
Why it matters
The Q3 earnings beat was modest, but the lowered Q4 outlook and sizable refinancing raise concerns about near‑term growth.
Market read
First report of Integra's Q3 results and guidance, with a $2.1B debt refinance, likely to move the stock.
What to watch
Potential upside from a faster recovery in Cincinnati and margin expansion if cost controls succeed.
Background
Integra LifeSciences is a medical device company focused on neurosurgery and tissue reconstruction.
Ticker impact
Integra LifeSciences posted Q3 results and lowered Q4 guidance while completing a $2.1B debt refinancing.
likely downside as investors price in weaker Q4 revenue and earnings.
Revenue guidance narrowed and lowered; EPS guidance also reduced, indicating softer demand in Tissue Reconstruction.
Market effects
May weigh on other medical device and tissue reconstruction firms.
Limited to U.S. healthcare equities.
Low; impact confined to sector.
Counterpoint
If the refinancing improves balance sheet flexibility, the stock could rebound on the back of lower financing costs.
Key entities
- CompanyIntegra LifeSciences Holdings Corporation
Issuer of the earnings and refinancing announcement.
